New Research on omega 3

Bigbear

The Kodiak
Trusted Member
1. UK Biobank Study (BMJ Medicine, 2024)



Participants: Over 415,000 individuals from the UK Biobank, monitored for 12 years.
Findings: Among individuals without cardiovascular disease, regular fish oil supplement use was associated with a 13% increased risk of developing atrial fibrillation (AFib) and a 5% higher risk of stroke. Conversely, in participants with existing heart disease, fish oil supplements were linked to a 15% reduction in progression from AFib to heart attack and a 9% decrease in progression from heart failure to death.
Conclusion: The effects of fish oil supplements may vary based on individual cardiovascular health status.
Source: https://www.theguardian.com/news/ar...sk-of-heart-conditions-and-stroke-study-finds


---

2. OMEMI Trial (Circulation, 2020)



Design: Randomized, placebo-controlled trial involving 1,027 elderly patients (aged 70–82) who had experienced a recent myocardial infarction.
Intervention: Daily supplementation with 1.8 grams of omega-3 PUFAs (930 mg EPA and 660 mg DHA) versus placebo, over two years.
Results: No significant difference in the primary composite outcome (all-cause death, nonfatal myocardial infarction, unscheduled revascularization, stroke, or hospitalization for heart failure) between the omega-3 and placebo groups. A non-significant trend toward increased incidence of AFib in the omega-3 group (7.2%) compared to placebo (4.0%).
Conclusion: Omega-3 supplementation did not confer additional cardiovascular benefits in this elderly post-MI population.
Source: https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2020/11/11/21/30/OMEMI


---

3. Meta-Analysis on Omega-3 and Atrial Fibrillation (Circulation, 2021)



Scope: Systematic review and meta-analysis of randomized controlled trials assessing the impact of long-term marine omega-3 fatty acid supplementation on AFib risk.
Findings: High-dose omega-3 supplementation (≥1 gram/day) was associated with an increased risk of developing AFib. The risk appeared to be dose-dependent, with higher doses correlating with greater risk.
Conclusion: While omega-3 fatty acids may have cardiovascular benefits, high-dose supplementation may elevate the risk of AFib.
Source: https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.121.055654
 
Top